Adverse event reports following yellow fever vaccination
- PMID: 18809449
- DOI: 10.1016/j.vaccine.2008.09.009
Adverse event reports following yellow fever vaccination
Abstract
Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.
Similar articles
-
Adverse event reports following yellow fever vaccination, 2007-13.J Travel Med. 2016 Jul 4;23(5). doi: 10.1093/jtm/taw045. Print 2016 May. J Travel Med. 2016. PMID: 27378369
-
Review of the risks and benefits of yellow fever vaccination including some new analyses.Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Expert Rev Vaccines. 2012. PMID: 22551029 Review.
-
Yellow fever vaccination: how much is enough?Vaccine. 2005 Jun 10;23(30):3908-14. doi: 10.1016/j.vaccine.2005.03.002. Epub 2005 Apr 2. Vaccine. 2005. PMID: 15917112
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
-
Prevention of yellow fever in persons traveling to the tropics.Clin Infect Dis. 2002 May 15;34(10):1369-78. doi: 10.1086/340104. Epub 2002 Apr 25. Clin Infect Dis. 2002. PMID: 11981733 Review.
Cited by
-
Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development.Sci Rep. 2024 May 12;14(1):10842. doi: 10.1038/s41598-024-60680-9. Sci Rep. 2024. PMID: 38735993 Free PMC article.
-
The conneXion between sex and immune responses.Nat Rev Immunol. 2024 Jul;24(7):487-502. doi: 10.1038/s41577-024-00996-9. Epub 2024 Feb 21. Nat Rev Immunol. 2024. PMID: 38383754 Free PMC article. Review.
-
Sex-Differential and Non-specific Effects of Vaccines Over the Life Course.Curr Top Microbiol Immunol. 2023;441:225-251. doi: 10.1007/978-3-031-35139-6_9. Curr Top Microbiol Immunol. 2023. PMID: 37695431 Free PMC article. Review.
-
Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.J Travel Med. 2023 Nov 18;30(7):taad037. doi: 10.1093/jtm/taad037. J Travel Med. 2023. PMID: 37000007 Free PMC article.
-
Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD.Vaccines (Basel). 2023 Feb 15;11(2):445. doi: 10.3390/vaccines11020445. Vaccines (Basel). 2023. PMID: 36851322 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical